{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000005","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.517183+00:00","generated_at":"2026-06-27T20:33:43.481133+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Castle Biosciences Chief Business Officer resigns; enters consulting agreement with vesting extension","bullets":["Bernhard Spiess resigns as CBO effective Dec 31, 2021; separation agreement signed Dec 29, 2021.","Receives accrued salary ($16,666.67), PTO payout ($72,783.74), and 2021 bonus (50% salary × board-approved corp attainment).","Consulting agreement at $250/hour through Dec 31, 2022; outstanding equity continues vesting during consulting term.","Non-competition for 1 year and non-solicitation for 3 years after consulting ends.","Company may terminate consulting agreement immediately for any reason."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000005","json":"https://secwatch.observer/filing/0001447362-22-000005.json","markdown":"https://secwatch.observer/filing/0001447362-22-000005.md","text":"https://secwatch.observer/filing/0001447362-22-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/0001447362-22-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/cstl-20211229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:33:43.481133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db3944ca96","claim":"Bernhard E. Spiess resigned as Chief Business Officer at CASTLE BIOSCIENCES INC.","evidence_excerpt":"Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/0001447362-22-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}